|
Search of: sleeping sickness | "Trypanosomiasis, African" - List Results - ClinicalTrials.gov
Search of: Sleeping Sickness | "Trypanosomiasis, African" - List Results - ClinicalTrials.gov
MedlinePlus
Medical Encyclopedia: Sleeping sickness
MedlinePlus
Medical Encyclopedia: Sleeping Sickness
Yellow Book - Chapter 4 - Trypanosomiasis, African (Afri | CDC Travelers' Health
Trypanosomiasis, African (African Sleeping Sickness)
Division of Parasitic Diseases - West African trypanosomiasis Fact Sheet
Division of Parasitic Diseases - West African trypanosomiasis Fact Sheet
African sleeping sickness
African Sleeping Sickness
DPDx - CDC Parasitology Diagnostic Web Site
DPDx - CDC Parasitology Diagnostic Web Site
Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice.
Immunopathology of experimental African Sleeping Sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice.
Glycosylphosphatidylinositol biosynthesis validated as a drug
target for African sleeping sickness
Glycosylphosphatidylinositol biosynthesis validated as a drug
target for African Sleeping Sickness
Division of Parasitic Diseases - Trypanosomiasis
Division of Parasitic Diseases - Trypanosomiasis
Trials Beginning on New Medication for Sleeping Sickness - US Department of State
"Immtech International, Inc. of Vernon Hills, Ill., a pharmaceutical company and a contributor to this drug development effort, has an exclusive, worldwide license to DB289 and related compounds developed by the UNC-based scientific consortium for African Sleeping Sickness and other devastating diseases such as TB, which together affect millions of people annually," Tidwell said. "Besides DB289, several potential drug candidates in early development appear to be promising for treating late stage African Sleeping Sickness, which occurs when the parasite over time enters the brain."
Prevention Guidelines Titles
Topic: African Sleeping Sickness
DPDx - CDC Parasitology Diagnostic Web Site
DPDx - CDC Parasitology Diagnostic Web Site
Search of: Sleeping Sickness - List Results - ClinicalTrials.gov
Search of: Sleeping Sickness - List Results - ClinicalTrials.gov
Dr. Louise Pearce
Dr. Louise Pearce volunteered to go alone to the Belgian Congo in 1920
to test a new drug she hoped would cure African Sleeping Sickness, a disease that was often fatal.
She received her M.D. from The Johns Hopkins University in 1912.
Looking for work, she wrote to Dr. Simon Flexner, Director of the Rockefeller Institute in New York City,
requesting a research position.
Dr. Flexner supported her application, and Dr. Louise Pearce became the first woman to work directly with him.
In 1910, an arsenic-based drug called Salvarsan was found to be an effective treatment for syphilis.
Scientists had hopes of developing other arsenic-based drugs.
Dr. Flexner asked his research team to try and find an arsenical compound for use against African Sleeping Sickness.
They succeeded. Tryparsamide, they found, destroyed the infectious agent of Sleeping Sickness in animals.
In 1919, these results were announced in the Journal of Experimental Medicine.
A severe outbreak of African Sleeping Sickness broke out in the Belgian Congo in 1920.
While in Africa, Dr. Pearce administered and studied the effects of the tryparsamide on seventy patients.
The results were spectacular: the parasites were driven from circulating blood within days
and totally eradicated within weeks.
Symptoms cleared up and general health was restored in a large proportion of even the most severe cases.
Belgian officials were impressed by the results. Dr. Pearce was awarded the Ancient Order of the Crown
and elected a member of the Belgian Society of Tropical Medicine.
Three decades later, in 1953, she was invited to Brussels
to receive the King Leopold III Prize and an award of ten thousand dollars.
After her success in the Belgian Congo, Dr. Pearce returned to the Rockefeller Institute,
and was promoted to Associate Member in 1923.
Teamed with Dr. Wade Hampton Brown, she studied susceptibility and resistance to infection.
They discovered they could transplant certain cancers from one rabbit t
African lymphoma
Next Term: African Sleeping Sickness
Three Deadly Parasite Genomes Sequenced
Three Deadly Parasite Genomes Sequenced
Yellow Book - Chapter 4 - Trypanosomiasis, American (Cha | CDC Travelers' Health
Previous - Chapter 4 : Trypanosomiasis, African (African Sleeping Sickness)
NIH Office of Technology Transfer (OTT)
NIH Office of Technology Transfer (OTT)
Trials Beginning on New Medication for Sleeping Sickness
"Immtech International, Inc. of Vernon Hills, Ill., a pharmaceutical company and a contributor to this drug development effort, has an exclusive, worldwide license to DB289 and related compounds developed by the UNC-based scientific consortium for African Sleeping Sickness and other devastating diseases such as TB, which together affect millions of people annually," Tidwell said. "Besides DB289, several potential drug candidates in early development appear to be promising for treating late stage African Sleeping Sickness, which occurs when the parasite over time enters the brain."
|